Trials / Completed

CompletedNCT04684446

Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19

A Phase I/II Single-Blinded Randomized Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of COVID 19

Status: Completed
Phase: Phase 1 / Phase 2
Study type: Interventional
Enrollment: 100 (actual)

Sponsor: R-Pharm · Industry
Sex: All
Age: 18 Years – 130 Years
Healthy volunteers: Accepted

Summary

The objective is to evaluate the safety and immunogenicity of AZD1222 given in combination with (either before or after) rAd26-S, for the prevention of COVID 19 in adults ≥ 18 years of age.

Conditions

COVID-19

Interventions

Type	Name	Description
BIOLOGICAL	AZD1222	Participants will receive 1 intramuscular (IM) injection of 5 ×1010 viral particles (vp) (nominal) of AZD1222 on Day 1 followed by rAd26-S 1×1011 viral particles (vp) (nominal) on Day 29 of the study
BIOLOGICAL	rAd26-S	Participants will receive 1 IM injection of rAd26-S on Day 1 followed by AZD1222 on Day 29

Timeline

Start date: 2021-09-15
Primary completion: 2021-11-26
Completion: 2022-03-29
First posted: 2020-12-24
Last updated: 2022-06-03

Locations

4 sites across 1 country: Russia

Source: ClinicalTrials.gov record NCT04684446. Inclusion in this directory is not an endorsement.